-
公开(公告)号：EP3369741A1
公开(公告)日：2018-09-05
申请号：EP17868497.3
申请日：2017-09-14
申请人： Hysensbio
发明人： PARK, Joo Hwang , LEE, Ji Hyun
摘要： Provided are a novel peptide, a polynucleotide encoding the peptide, an expression vector including the polynucleotide, and a pharmaceutical composition including the peptide, a quasi-drug composition including the peptide, and a health functional food composition including the peptide.
-
52.发明公开
公开(公告)号：EP3354664A1
公开(公告)日：2018-08-01
申请号：EP16849046.4
申请日：2016-09-26
发明人： LEE, Jong Soo , CHOI, Seong Ho , CHOI, Jae Hyuk , KIM, Sang Yun , JUNG, Sung Youb , KWON, Se Chang
IPC分类号： C07K19/00
CPC分类号： A61K47/6849 , A61K38/1825 , A61K38/2278 , A61K38/26 , A61K38/28 , A61K47/60 , A61K47/6811 , C07K19/00
摘要： The present invention relates to a physiologically active polypeptide conjugate comprising multiple physiologically active polypeptides and immunoglobulin Fc regions, use thereof, and a preparation method thereof.
-
53.发明公开
公开(公告)号：EP3331864A2
公开(公告)日：2018-06-13
申请号：EP16833369.8
申请日：2016-08-04
发明人： LEE, Jaekwang , KIM, Yuntae , LEE, Chang Sik , SONG, Hyeseung , GWAK, Dal-Yong , LEE, Jaeyoung , OH, Jung Taek , LEE, Chang Gon , KIM, II Hyang
IPC分类号： C07D271/10 , C07D413/12 , A61K31/4245 , A61K31/5377 , A61K31/497
CPC分类号： C07D271/10 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/10 , C07D491/10
摘要： The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.
-
公开(公告)号：EP3328497A1
公开(公告)日：2018-06-06
申请号：EP15802045.3
申请日：2015-11-25
IPC分类号： A61P35/02
CPC分类号： A61K47/6867 , A61K47/6803
摘要： The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for in treating disorders characterized by the presence of CD25+ve cells.
-
公开(公告)号：EP3320112A1
公开(公告)日：2018-05-16
申请号：EP16738731.5
申请日：2016-07-08
申请人： BerGenBio ASA
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N2800/52 , G01N2800/60 , G01N2800/7028
摘要： The use of PHGDH as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of PHGDH modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring PHGDH expression and/or activity.
-
56.发明公开
公开(公告)号：EP3316908A1
公开(公告)日：2018-05-09
申请号：EP16818720.1
申请日：2016-06-29
发明人： JIANG, Wei-dong , LIN, Pei-Hua , TSENG, Chi-ling
IPC分类号： A61K39/395 , A61K38/18 , C07K14/475 , C07K16/22
CPC分类号： A61K39/39558 , A61K39/44 , A61K2039/505 , A61P11/00 , A61P35/00 , C07K14/71 , C07K16/2863 , C07K2317/21 , C07K2317/70 , C07K2317/73 , C07K2317/76 , G01N33/74
摘要： Provided are anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-VEGFR2 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-VEGFR2 antibodies and antigen binding fragments thereof. Also provided are related pharmaceutical compositions comprising anti-VEGFR2 antibodies (or antigen binding fragments thereof) and methods of their use in the treatment of pathological conditions characterized by excessive angiogenesis.
-
公开(公告)号：EP3313384A1
公开(公告)日：2018-05-02
申请号：EP16815312.0
申请日：2016-06-23
发明人： BOGIN, Vlad , ICHIM, Thomas
CPC分类号： A61K33/00 , A61K9/0073 , A61P25/28 , G01N33/6863
摘要： Described are compositions of matter and protocols useful for treatment of neurological and other disorders associated with inflammatory activities. In some embodiments the invention provides means of modulating neuroinflammation through administration of noble gas containing compositions. In other aspects, the invention provides means of modulating stem cell compartments to enhance endogenous reparative activities or to synergize with existing treatments.
-
公开(公告)号：EP3283123A1
公开(公告)日：2018-02-21
申请号：EP16716607.3
申请日：2016-04-15
CPC分类号： A61K47/6849 , A61K45/06 , A61K47/6803 , A61K2039/505 , A61P35/00 , C07K16/2866 , C07K16/30 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , Y02P20/55
摘要： Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds CD25 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
-
公开(公告)号：EP3283117A1
公开(公告)日：2018-02-21
申请号：EP16716582.8
申请日：2016-04-15
CPC分类号： A61K47/6803 , A61K47/6849 , A61P35/00 , C07K16/30 , Y02P20/55
摘要： Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody that binds CD19 and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
-
公开(公告)号：EP3283116A1
公开(公告)日：2018-02-21
申请号：EP16716581.0
申请日：2016-04-15
CPC分类号： A61K47/6851 , A61K31/5517 , A61K45/06 , A61K47/6803 , A61K47/6849 , A61K47/6867 , A61K2039/505 , A61K2039/545 , A61K2039/572 , A61P35/00 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/522 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94 , Y02P20/55
摘要： Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody which binds AXL, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
-
-
-
-
-
-
-
-
-
搜索结果
210 条记录 (耗时 0.079 秒)
